Abstract
Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.
| Original language | English |
|---|---|
| Pages (from-to) | 564-569 |
| Number of pages | 6 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 32 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2009 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. / Choi, Jong Won; Park, Junyong; Ahn, SangHoon; Yoon, Ki Tae; Ko, Heung Kyu; Lee, Do Yun; Lee, Jong Tae; Kim, Kyung Sik; Choi, Jin Sub; Han, KwangHyub; Chon, Chae Yoon; kim, doyoung.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 32, No. 6, 01.12.2009, p. 564-569.Research output: Contribution to journal › Article
TY - JOUR
T1 - Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection
AU - Choi, Jong Won
AU - Park, Junyong
AU - Ahn, SangHoon
AU - Yoon, Ki Tae
AU - Ko, Heung Kyu
AU - Lee, Do Yun
AU - Lee, Jong Tae
AU - Kim, Kyung Sik
AU - Choi, Jin Sub
AU - Han, KwangHyub
AU - Chon, Chae Yoon
AU - kim, doyoung
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.
AB - Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.
UR - http://www.scopus.com/inward/record.url?scp=73349099035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73349099035&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e3181967da0
DO - 10.1097/COC.0b013e3181967da0
M3 - Article
C2 - 19564783
AN - SCOPUS:73349099035
VL - 32
SP - 564
EP - 569
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 6
ER -